Huntsville, Ala. — HudsonAlpha associate company CFD Research Corporation recently completed its spinout of SynVivo, LLC.
“CFDRC’s mission is to develop cutting-edge technologies into commercially viable solutions,” said retired Lt. Gen. Joe Cosumano, President and CEO of CFDRC. “SynVivo represents the most recent fulfillment of our corporate strategy for commercialization of breakthrough technologies.”
SynVivo, whose name is derived from synthetic in vivo, is a disruptive technology with a goal to revolutionize drug discovery and personalized medicine by providing the most realistic and dynamic in vitro platform for cellular behavior and drug response. More information about the technology can be found at www.synvivobio.com. Already at a commercial stage, SynVivo has a diverse customer base of clients from research institutions, biotechs and pharma.
To accelerate vertical growth of the technology, SynVivo has hired C. Richard Piazza as the President and CEO. Piazza is a leading industry veteran with extensive healthcare experience in biotech, pharma and MedTech. He has managed both start-ups as well as large multi-nationals and has earned a reputation for successful new product launches and introductions. “SynVivo’s technology is poised to transform disease modeling and drug discovery and usher in true personalized medicine,” said Piazza, “and I am excited to be part of the team.”
“All of us at HudsonAlpha welcome Mr. Piazza to Huntsville and the biotech campus,” said Carter Wells, Vice President for Economic Development at HudsonAlpha Institute for Biotechnology. “CFDRC continues to be an outstanding part of the HudsonAlpha family, and we look forward to watching SynVivo grow and flourish.”
SynVivo, LLC was founded in 2014 as a spin-out from CFD Research Corporation to commercialize the SynVivo family of cell-based assays. SynVivo is a microchip platform that provides a physiologically realistic microfluidic environment that allows the real-time study of cellular behavior and drug delivery. SynVivo recreates the complex in vivo vasculature including scale, morphology, fluidics and cellular interactions in an in vitro environment enabling basic and applied life sciences research. SynVivo is being actively used in Pharma, Biotech, Clinical, and Academic labs around the world for applications in inflammation, oncology, neurology, and toxicology. Our scientific and technological innovation record is strong and we continue to develop and validate new in vitro assays in collaboration with our partners. We invite you to use our products, services and technical solutions, which will afford your organization new opportunities in obtaining faster, cost-effective, more reliable and relevant results compared to the traditional assays and 2D in vitro systems. SynVivo is located in Huntsville, Alabama, USA in Cummings Research Park Biotech Campus co-located with the HudsonAlpha Institute for Biotechnology.
HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological problems. Its mission is three-fold: sparking scientific discoveries that can impact human health and well-being; fostering biotech entrepreneurship; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus allow serendipity to yield results in medicine and agriculture. Since opening in 2008, HudsonAlpha, under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, has built a name for itself in genetics and genomics research and biotech education, and boasts 27 biotech companies on campus.